Stryker (NYSE:SYK) Price Target Raised to $445.00

Stryker (NYSE:SYK) had its price target boosted by stock analysts at JPMorgan Chase & Co. from $420.00 to $445.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the medical technology company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 12.68% from the stock’s current price.

Several other research analysts also recently commented on SYK. Citigroup boosted their price objective on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. JMP Securities restated a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Piper Sandler reiterated an “overweight” rating and issued a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Wells Fargo & Company increased their target price on shares of Stryker from $405.00 to $427.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Finally, BTIG Research lifted their price target on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $412.55.

Stryker Stock Performance

Shares of NYSE SYK opened at $394.92 on Wednesday. Stryker has a one year low of $310.74 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The firm has a market cap of $150.55 billion, a price-to-earnings ratio of 42.33, a P/E/G ratio of 2.68 and a beta of 0.95. The stock’s fifty day moving average price is $376.44 and its two-hundred day moving average price is $361.98.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same period in the prior year, the business earned $3.46 earnings per share. On average, equities analysts forecast that Stryker will post 12.06 EPS for the current year.

Insider Buying and Selling

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.50% of the stock is owned by insiders.

Institutional Trading of Stryker

Hedge funds and other institutional investors have recently bought and sold shares of the business. Opal Wealth Advisors LLC raised its holdings in shares of Stryker by 1.6% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock worth $654,000 after acquiring an additional 28 shares during the last quarter. Wingate Wealth Advisors Inc. purchased a new stake in shares of Stryker in the fourth quarter worth approximately $78,000. Savant Capital LLC lifted its holdings in shares of Stryker by 8.5% in the fourth quarter. Savant Capital LLC now owns 7,592 shares of the medical technology company’s stock valued at $2,734,000 after purchasing an additional 596 shares in the last quarter. Harbour Trust & Investment Management Co boosted its position in shares of Stryker by 1.1% during the fourth quarter. Harbour Trust & Investment Management Co now owns 42,831 shares of the medical technology company’s stock valued at $15,421,000 after buying an additional 484 shares during the last quarter. Finally, Canvas Wealth Advisors LLC grew its holdings in Stryker by 4.4% during the fourth quarter. Canvas Wealth Advisors LLC now owns 1,859 shares of the medical technology company’s stock worth $669,000 after buying an additional 78 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.